![Jason Ruth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Jason R.
Ruth is currently Chief Business Officer at 5:01 Acquisition Corp.
since 2020, Chief Scientific Officer at Castleman Disease Collaborative Network since 2014, and Sector Lead at.
Wellington Management Co. LLP (Private Equity) starting in 2024.
Former roles include Principal at 5AM Venture Management LLC from 2020 to 2022 and Partner at Merck Research Ventures.
Education includes a doctorate from the University of Pennsylvania conferred in 2014 and an undergraduate degree from the University of California, Irvine conferred in 2007.
Postes actifs de Jason Ruth
| Sociétés | Poste | Début |
|---|---|---|
| 501 ACQU | Corporate Officer/Principal | 01/09/2020 |
Castleman Disease Collaborative Network
 Castleman Disease Collaborative Network The private company is based in Paso Robles. The Castleman Disease Collaborative Network (CDCN) is a patient-founded nonprofit organization established in 2012 that focuses on accelerating research, improving treatment, and enhancing patient care for Castleman disease, a rare and complex group of inflammatory disorders. CDCN connects physicians, researchers, patients, and loved ones worldwide through online platforms, registries, forums, and summits to foster collaboration and scientific progress. The organization uses a community-driven approach to prioritize research questions, recruit scientists, and fund targeted studies, with a comprehensive research pipeline that includes patient enrollment, biospecimen collection, data analysis, and dissemination of findings. CDCN emphasizes drug repurposing and identification of new therapeutic targets, with clinical trials underway for treatments beyond the only FDA-approved drug for idiopathic multicentric Castleman disease. Key initiatives include the ACCELERATE natural history registry, the Castleman Disease Expert Panel, the IMCD Treatment Target Dashboard, and the Roadmap Project for drug repurposing. CDCN provides resources for patients, physicians, and researchers, such as toolkits, referral lists, support networks, educational materials, and regular updates. | Directeur Technique/Scientifique/R&D | 01/03/2014 |
Wellington Management Co. LLP (Private Equity)
 Wellington Management Co. LLP (Private Equity) Investment ManagersFinance Wellington Management invests in companies located in the United States. The firm targets companies operating in the fields of consumer, technology, healthcare, financial services, climate technology and biotechnology sectors. It provides financing for early stage to later stage capital requirements. | Private Equity Investor | 01/12/2024 |
Anciens postes connus de Jason Ruth
| Sociétés | Poste | Fin |
|---|---|---|
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Private Equity Investor | 01/12/2024 |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Analyste en capital-investissement | 01/01/2020 |
Formation de Jason Ruth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Finance |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Finance |
Wellington Management Co. LLP (Private Equity)
Wellington Management Co. LLP (Private Equity) Investment ManagersFinance Wellington Management invests in companies located in the United States. The firm targets companies operating in the fields of consumer, technology, healthcare, financial services, climate technology and biotechnology sectors. It provides financing for early stage to later stage capital requirements. | Finance |
5:01 Acquisition Corp.
 5:01 Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Castleman Disease Collaborative Network
Castleman Disease Collaborative Network The private company is based in Paso Robles. The Castleman Disease Collaborative Network (CDCN) is a patient-founded nonprofit organization established in 2012 that focuses on accelerating research, improving treatment, and enhancing patient care for Castleman disease, a rare and complex group of inflammatory disorders. CDCN connects physicians, researchers, patients, and loved ones worldwide through online platforms, registries, forums, and summits to foster collaboration and scientific progress. The organization uses a community-driven approach to prioritize research questions, recruit scientists, and fund targeted studies, with a comprehensive research pipeline that includes patient enrollment, biospecimen collection, data analysis, and dissemination of findings. CDCN emphasizes drug repurposing and identification of new therapeutic targets, with clinical trials underway for treatments beyond the only FDA-approved drug for idiopathic multicentric Castleman disease. Key initiatives include the ACCELERATE natural history registry, the Castleman Disease Expert Panel, the IMCD Treatment Target Dashboard, and the Roadmap Project for drug repurposing. CDCN provides resources for patients, physicians, and researchers, such as toolkits, referral lists, support networks, educational materials, and regular updates. |
